Clinical trials: Adjuvant Drug Therapy
Heroin Dependence
Laser Meridian Massage in Heroin Addicts
A case-controlled study is conducted to investigate the effect of adjuvant laser meridian massage in heroin addicts with methadone treatment and establish the model of laser meridian massage treatment for drug addiction.
- Trial name
- NCT04003077
- Testing
- laser meridian massage
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Depression, Stage I Breast Cancer
Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
RATIONALE: Chemotherapy may affect various factors that can lead to weight gain. PURPOSE: Clinical trial to evaluate factors that may affect weight gain in women receiving adjuvant chemotherapy for stage I, stage II, or stage…
- Conditions
- Depression, Stage I Breast Cancer, Stage IIIA Breast Cancer, Nutrition
- Trial name
- NCT00019643
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer
Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer
This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant chemotherapy for 1-3 positive lymph node, ER+/HER2…
- Trial name
- CLOVER (NCT03926091)
- Testing
- Docetaxel, Cyclophosphamide
- Where
- 14 sites in China
- Volunteers
- 2,172 people
- Sponsor
- Fudan University
Colon Cancer
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp).
- Trial name
- FOxTROT2France (NCT06293625)
- Testing
- Folfox, Surgery
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colon Cancer
Early Commencement of Adjuvant Chemotherapy for Colon Cancer
This study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after…
- Trial name
- ECTX (NCT01460589)
- Testing
- timing to initiate the adjuvant FOLFOX chemotherapy
- Where
- 2 sites in South Korea
- Volunteers
- 303 people
- Sponsor
- Kyungpook National University Hospital
Breast Cancer
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
- Trial name
- NCT03355261
- Testing
- complete remission (CR) group, partial remission (PR) group, stable disease (SD) group
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Breast Cancer
CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)
This observational study is restricted to postmenopausal women with hormone-sensitive early breast cancer, who have decided to take prescribed adjuvant use of AIs, anastrozole or letrozole, according to the current product SmPCs.
- Trial name
- CARIATIDE (NCT00681122)
- Where
- 164 sites in Australia, Austria and 16 more
- Volunteers
- 2,600 people
- Sponsor
- AstraZeneca
Stage II Colon Cancer, Adjuvant Chemotherapy
Adjuvant Chemotherapy in High Risk Stage II Colon Cancer
Benefit of adjuvant chemotherapy after curative surgery for stage II Colon Cancer is still debated. Several high-risk features may help to stratify stage II cancer patients into groups that will truly benefit from adjuvant…
- Trial name
- NCT04303429
- Testing
- FOLFOX/XELOX/Capecitabine
- Volunteers
- 962 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer…
- Trial name
- NCT07114666
- Testing
- XH001, Chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00089024
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Fallopian Tube Cancer, Ovarian Cancer
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00838656
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 4 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Warwick Medical School
Head and Neck Cancer
Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003637
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National Cancer Centre, Singapore
Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04267237
- Testing
- Atezolizumab, RO7198457
- Sponsor
- Hoffmann-La Roche
Vulvar Cancer
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006096
- Testing
- cisplatin, radiation therapy
- Where
- 30 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Quality of Life
Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer
This study is examine the effect of the addition of naturopathic on immunologic and/or inflammatory parameters and/or quality of life in women receiving neoadjuvant chemotherapy for breast cancer.
- Trial name
- NCT02486796
- Testing
- Reishi mushroom extract, Coenzyme Q10, Melatonin
- Volunteers
- 5 people
- Sponsor
- Midwestern Regional Medical Center
Pancreatic Adenocarcinoma
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
Phase Ib clinical trial using Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP) in order to stimulate/induce both innate and adaptive immunity by activating T-cells and Natural Killer (NK) cells, combined…
- Trial name
- NCT04627246
- Testing
- Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Gastric Cancer
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
The purpose of this study is to evaluate the efficacy and safety of combined chemotherapy and radiotherapy (in comparison to chemotherapy alone) as adjuvant treatment after surgery for gastric cancer.
- Trial name
- NCT00407186
- Testing
- cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
- Where
- Netherlands
- Volunteers
- 788 people
- Sponsor
- Dutch Colorectal Cancer Group
Colorectal Neoplasms, Anesthesia
Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer in the world with a high postoperative mortality (2 - 6%) as well as a low 5-year survival (40%).
- Conditions
- Colorectal Neoplasms, Anesthesia, Drug Therapy, Surgery
- Trial name
- ENCORE (NCT04493905)
- Where
- Sweden
- Volunteers
- 5,500 people
- Sponsor
- European Society of Anaesthesiology
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colo-rectal Cancer, Colorectal Cancer Recurrent
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients.
- Trial name
- NCT06654622
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.